Eculizumab administration for myasthenia gravis also stabilizes thrombogenicity of catastrophic antiphospholipid syndrome

Q4 Immunology and Microbiology

Clinical and Experimental Neuroimmunology Pub Date : 2024-04-22 DOI:10.1111/cen3.12790

Sunao Takahashi, Nobuo Sanjo, Ryuji Koike, Takanori Yokota

{"title":"Eculizumab administration for myasthenia gravis also stabilizes thrombogenicity of catastrophic antiphospholipid syndrome","authors":"Sunao Takahashi, Nobuo Sanjo, Ryuji Koike, Takanori Yokota","doi":"10.1111/cen3.12790","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The co-occurrence of myasthenia gravis and primary antiphospholipid syndrome (APS) is rare. Notably, both the diseases share common complement-mediated mechanisms.</p>\n </section>\n \n <section>\n \n <h3> Case Presentation</h3>\n \n <p>A 36-year-old woman, who was previously diagnosed with myasthenia gravis and APS, developed multiple embolisms, involving the brain, kidney and spleen, with severe anemia and platelet reduction. She was diagnosed as catastrophic APS, and intensive immunotherapies, including plasma exchange, high-dose corticosteroid and rituximab, were introduced. After these therapies, symptoms of both APS and myasthenia gravis worsened, consistent with elevation of immunoglobulin G anti-beta-2-glycoprotein-I antibody and anti-acetylcholine receptor antibody. We started eculizumab, which resulted in stabilizing the disease activity of both diseases without notable adverse events.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Eculizumab can be effective for controlling multiple complement-mediated pathophysiology.</p>\n </section>\n </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Neuroimmunology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen3.12790","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Immunology and Microbiology","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The co-occurrence of myasthenia gravis and primary antiphospholipid syndrome (APS) is rare. Notably, both the diseases share common complement-mediated mechanisms.

Case Presentation

A 36-year-old woman, who was previously diagnosed with myasthenia gravis and APS, developed multiple embolisms, involving the brain, kidney and spleen, with severe anemia and platelet reduction. She was diagnosed as catastrophic APS, and intensive immunotherapies, including plasma exchange, high-dose corticosteroid and rituximab, were introduced. After these therapies, symptoms of both APS and myasthenia gravis worsened, consistent with elevation of immunoglobulin G anti-beta-2-glycoprotein-I antibody and anti-acetylcholine receptor antibody. We started eculizumab, which resulted in stabilizing the disease activity of both diseases without notable adverse events.

Conclusions

Eculizumab can be effective for controlling multiple complement-mediated pathophysiology.

Abstract Image

查看原文本刊更多论文

服用依库珠单抗治疗重症肌无力也能稳定灾难性抗磷脂综合征的血栓形成率

重症肌无力和原发性抗磷脂综合征（APS）并发的情况非常罕见。一名曾被诊断患有重症肌无力和原发性抗磷脂综合征的 36 岁女性出现了多发性栓塞，累及大脑、肾脏和脾脏，并伴有严重贫血和血小板减少。她被诊断为灾难性 APS，并接受了强化免疫治疗，包括血浆置换、大剂量皮质类固醇和利妥昔单抗。经过这些治疗后，APS 和重症肌无力的症状都恶化了，与免疫球蛋白 G 抗-β-2-糖蛋白-I 抗体和抗乙酰胆碱受体抗体的升高相一致。我们开始使用依库珠单抗，结果这两种疾病的活动性都趋于稳定，而且没有出现明显的不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Neuroimmunology Immunology and Microbiology-Immunology and Microbiology (miscellaneous)

CiteScore

1.60

自引率

0.00%

发文量